What this trial means for you
This study is recruiting now at 16 US sites. It's studying Semaglutide, Placebo for overweight, obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Female or male (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) of 1. ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease. OR 2. ≥ 30.0 kg/m\^2. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records. * HbA1c ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.
Study sites by state
Alabama
- Uni of Alabama at Birmingham, Birmingham · Opening soon
California
- Headlands Research California, LLC, Escondido · Opening soon
- National Research Institute - Huntington Park, Huntington Park · Opening soon
- Los Angeles Institute for Metabolic Research, Los Angeles · Opening soon
Florida
- ERG Holding Company, LLC / Evolution Research Group, LLC, Delray Beach · Opening soon
- ERG Holding Company, LLC / Evolution Research Group, LLC, Fort Myers · Opening soon
- Jedidiah Clinical Research, Tampa · Opening soon
Hawaii
- East West Med Res Inst, Honolulu · Opening soon
Kentucky
- L-MARC Research Center, Louisville · Opening soon
Missouri
- StudyMetrix Research LLC, City of Saint Peters · Opening soon
Nevada
- Jubilee Clinical Research, Inc., Las Vegas · Opening soon
Oregon
- Corvallis Clinic PC Clinical Research Department, Corvallis · Opening soon
Pennsylvania
- UPA Ctr Weight and Eating Dis, Philadelphia · Opening soon
South Carolina
- Spartanburg Medical Research, Spartanburg · Opening soon
Texas
- Cedar Health Research, Dallas · Opening soon
Virginia
- Selma Medical Associates, Winchester · Opening soon
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.